Europe
One day after GlaxoSmithKline began to outline some of the broad strokes of splitting the company into two separate entities, more details are coming into place – particularly staffing concerns over the integration of the company’s vaccine business into its pharma operations.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
Boston is getting a new tenant focused on rare diseases. Italian pharma company Chiesi Farmaceutici S.p.A is launching a U.S.-based subsidiary Chiesi Global Rare Diseases with a focus on advancing research and new product development for rare and ultra-rare diseases.
Recipharm announced on 4 February 2020 that the offer to acquire Consort Medical plc had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020.
Findacure co-founder will apply extensive drug repurposing and rare disease expertise to progress Healx’s drug candidates into the clinic.
Pharma and life science companies from across the globe provide updates on their pipelines and businesses.
One entity will focus on pharmaceuticals and drug development, while the other will be aimed at consumer healthcare.
Active Biotech announced that its board of directors has approved the company’s new direction. The focus is on the company’s wholly-owned lead assets, laquinimod and tasquinimod.
Cellectricon, a collaborative services provider dedicated to advancing drug discovery and research in the areas of chronic pain and neurodegenerative diseases announces a collaboration with StressMarq Biosciences.
PRESS RELEASES